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Background: Bevacizumab has been suggested as a new treatment modality for cerebral radiation necrosis due to
its ability to block the effects of vascular endothelial growth factor (VEGF) in leakage-prone capillaries, though its
use still remains controversial in clinical practice.
Methods: The use of bevacizumab in 17 patients with symptomatic cerebral radiation necrosis poorly controlled
with dexamethasone steroid treatments was examined between March 2010 and January 2012. Bevacizumab
therapy was administered for a minimum of two cycles (7.5 mg/kg, at two-week interval) with a median of four
bevacizumab injections. Changes in bi-dimensional measurements of the largest radiation necrosis lesions were
observed by gadolinium-enhanced and T2-weighted magnetic resonance imaging (MRI). Additionally,
dexamethasone dosage, Karnofsky performance status (KPS), adverse event occurrence and associated clinical
outcomes were recorded for each patient.
Results: MRI analysis revealed that the average reduction was 54.9% and 48.4% in post-gadolinium and
T2-weighted sequence analysis, respectively. Significant clinical neurological improvements were expressed in 10
patients according to KPS values. Dexamethasone reduction was achieved four weeks after initiation of
bevacizumab in all patients, with four patients successfully discontinuing dexamethasone treatment. Mild to
moderate bevacizumab-related adverse events, such as fatigue, proteinuria and hypertension were observed in
three patients. Upon follow-up at 4 to 12 months, 10 patients showed clinical improvement, and 7 patient deaths
occurred from tumor progression (5 patients), recurrent necrosis (1 patient), and uncontrolled necrosis-induced
edema (1 patient).
Conclusions: These findings suggest bevacizumab as a promising treatment for cerebral radiation necrosis induced
by common radiation therapies, including external beam radiotherapy (EBRT), stereotactic radiosurgery (SRS), and
fractionated stereotactic radiotherapy (FSRT).
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Cerebral radiation necrosis, typically manifesting as a
necrotic white matter lesion, is one of the most dreaded
toxicities associated with radiation therapies targeting
brain tissues. The condition often appears three or more
months after treatment, with treatment volume and ra-
diation dosage being the two most important predictors
of occurrence and severity. Clinical appearance of radia-
tion necrosis has historically been treated by application
of corticosteroids; however, relapse frequently occurs* Correspondence: janetcyj@163.com
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reproduction in any medium, provided the orupon steroid discontinuation. Also, poor patient res-
ponse to conventional steroid dosages has been previously
observed, including adverse effects such as behavioral
changes, altered sleep patterns and changes in appetite.
Recent research suggests that therapeutic anticoagulation
and hyperbaric oxygen therapy may provide some relief of
these symptoms, but the efficacy of these treatments is
still controversial [1]. Alternatively, surgical decompres-
sion of radiation necrosis lesions can provide a beneficial
palliative effect; however, this treatment does not reverse
the necrotic process in the majority of patients [2].
Bevacizumab is a humanized murine monoclonal anti-
body that is used directly against vascular endothelialtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of a variety of solid tumors [3]. A growing number of
researchers have published positive findings using beva-
cizumab (Avastin, Genentech, San Francisco, CA, USA)
as a treatment strategy for cerebral radiation necrosis
due to its ability to block the effects of VEGF in leakage-
prone capillaries [3,4]. A randomized controlled clinical
trial further demonstrated class I evidence of the efficacy
of bevacizumab treatment for progressive radiation necro-
sis [5]. Despite these positive results, there remains con-
troversy pertaining to the efficacy of this treatment, with
some researchers claiming that bevacizumab treatment
reverses cerebral radiation necrosis effectively [6], while
others claim that such treatment increases the risk for
over-pruning of blood vessels that could potentially exa-
cerbate cerebral radiation necrosis [7].
The pathogenesis of cerebral radiation necrosis is
thought to be initiated by endothelial cell dysfunction as-
sociated with the release of VEGF, a substance capable of
disrupting the blood brain barrier [8]. Previously, VEGF
was referred to as a “vascular permeability factor” with the
potential to cause capillary endothelial leakage in cerebral
tissues [9]. Thus, VEGF is likely to play a key role in ra-
diation necrosis development [10]. When it is released in
the presence of hypoxia and necrosis, increased perme-
ability of the blood–brain barrier and subsequently in-
creased edema result [11]. The breakdown of the blood
brain barrier leads to significant edema formation that is
readily apparent through T2-weighted MRI, fluid attenu-
ated inversion recovery (FLAIR) images, and T1-weighted
gadolinium-enhanced MRI. Given its association with
radiation necrosis and blood–brain barrier dysfunction,
VEGF may become a logical putative therapeutic target
for the reversal of edema achieved by preventing VEGF
from reaching its capillary targets [3].
The current study reports on the findings observed at
a single clinical facility in China resulting from bevacizu-
mab treatment in patients with cerebral radiation necrosis
not well controlled with dexamethasone treatments.
Methods
A total of 17 symptomatic cerebral radiation necrosis
patients aged 13 to 71 years (median: 48), evidencing no
improvement upon treatment with the steroid dexa-
methasone, were selected for bevacizumab therapy treat-
ment at Shanghai Gamma Knife Hospital between March
2010 and January 2012. Full patient profiles are listed in
Table 1. Hematology analysis, biochemistry tests and pa-
tient history were analyzed in each case, resulting in exclu-
sion based on occurrence of major surgical procedures or
traumatic injuries within the past 28 days, uncontrolled
hypertension, cardiovascular or cerebrovascular disease
within the last six months, coagulopathy with an increased
risk of bleeding, proteinuria or renal dysfunction, andnon-healing wounds or ulcers. MRI imaging was applied
prior to bevacizumab treatment in order to exclude cere-
bral hemorrhaging. All data were prospectively recorded
and analyzed. Approval was obtained from the Ethics
Committee of Shanghai Gamma-knife Hospital. Each
patient provided written informed consent prior to treat-
ment and inclusion in the present study.
Pathological examination revealed various histological
types in original tumor tissues, including glioblastoma,
anaplastic astrocytoma, anaplastic oligodendroglioma,
arteriovenous malformation (AVM), metastatic brain
tumor, meningioma and fibrous dysplasia of bone. All
patients had previously undergone conventional radiation
therapy using external beam radiation therapy (EBRT),
stereotactic radiosurgery (SRS), or cyberknife treatment
system based fractionated stereotactic radiotherapy
(FSRT) either with or without concurrent chemotherapy.
Of the 17 included patients, 2 patients had received prior
SRS, 3 patients had received cyberknife treatment system
based FSRT and 10 patients had received EBRT only. The
two patients previously treated with conventional whole
brain radiotherapy received a second course of radiother-
apy with SRS due to tumor recurrence.
Diagnosis of cerebral radiation necrosis was based on
the clinical presentations and radiologic imaging fin-
dings, including findings from magnetic resonance ima-
ging (MRI), magnetic resonance spectroscopy (MRS),
perfusion MRI, and 18F-2-fluro-D-deoxy-glucose-positron
emission tomography (FDG-PET). MRI images demons-
trated an enhanced irradiated field with increased
T2-weighted signals in the surrounding brain parenchyma.
Radiation necrosis in MRS analysis was characterized by
decreased peaks in Cho, NAA and Cr, low Cho/Cr values,
and elevated Lip-Lac/Cho values compared with healthy
brain tissues [12]. FDG-PET scans showed no uptake of
radionuclides, thus ruling out tumor progression. Notably,
imaging scans clearly evidencing radiation necrosis can-
not exclude the possibility of the presence of a small
number of living tumor cells in or surrounding the
lesion. Thus, such determination methods relying
primarily on imaging indicate only that radiation necro-
sis is the primary cause of radiographic enhancement and
perilesional edema.
All 17 patients were treated with the steroid dexa-
methasone (median dose of 5 mg, three times daily, two
to four weeks) with no significant improvement in symp-
toms or MRI findings. All patients underwent MRI ima-
ging prior to bevacizumab treatment in order to establish
a baseline imaging profile. Similarly, all but two patients
underwent MRS. Intravenous bevacizumab treatment was
then started at 7.5 mg/kg for a minimum of two treat-
ments with a two-week interval between treatments, with
individual treatments administered over the course of
90 minutes. Primary response assessment was performed























1 70 M Colon cancer SRS 17 Gy Left temporal 6 0 0 4 30! 30 15! 12.5
2 13 F Anaplastic
Astrocytoma
EBRT 56 Gy Right
thalamus
18 75 60 9 50! 70 10! 0
3 71 M Colon cancer EBRT 36 Gy Left frontal 4 65 10 6 40! 80 15! 5
4 52 F meningioma EBRT 60 Gy Right frontal 180 80 60 8 60! 90 10! 2.5
5 71 M Lung cancer FSRT
31.5 Gy/3 fx
Left occipital 7 87 78 8 50! 90 15! 0
6 48 M Glioblastoma EBRT 60 Gy Left frontal 7 80 75 5 50! 70 10! 2.5
7 32 F Anaplastic
oligodendroglioma
EBRT 60 Gy Right frontal 40 50 45 4 50! 70 15! 10
8 67 F Colon cancer 1.EBRT
39 Gy /13 fx
Right frontal 1 52 78 4 50! 90 15! 0
2.SRS 16 Gy
9 23 M AVM SRS 16 Gy Left basal
ganglia
21 50 40 3 70! 80 10! 5
10 26 M Fibrous dysplasia
of bone
EBRT 70 Gy Brain stem 132 65 55 4 50! 70 17.5! 5
11 62 M Glioblastoma EBRT 60 Gy Left frontal 9 73 61 8 30! 50 15! 5
12 65 M Glioblastoma EBRT 60 Gy Right frontal 4 30 45 6 60! 70 10! 2.5




15 60 50 8 50! 90 15! 2.5




4 33 76 6 60! 90 15! 2.5
15 46 M Lung cancer 1.EBRT
30 Gy/10 fx
Left occipital 5 50 30 8 60! 80 12.5! 5
2.SRS 16 Gy
16 34 M Glioblastoma EBRT 60 Gy Right
temporal
5 75 54 4 60! 80 15! 5
17 55 M Glioblastoma EBRT 56 Gy Right
temporal
6 60 65 8 40! 60 10! 0
Abbreviations: AVM, arteriovenous malformation; EBRT, external beam radiation therapy; F, female; FSRT, fractionated stereotactic radiotherapy; KPS, Karnofsky
performance status; M, male; RT, radiation treatment; SRS, stereotactic radiosurgery; T2W, T2-weighted MRI.
Note: * Karnofsky performance scores were assessed immediately prior to treatment and at four weeks after treatment initiation.
** Amounts of dexamethasone (mg/day) immediately prior to the treatment and four weeks after treatment initiation.
# pretreatment! post two injections of bevacizumab.
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every eight weeks thereafter. Notably, patients received
only a single round of bevacizumab therapy, and no
second round treatments were administered to treat
recurrent radiation necrosis or uncontrolled edema.
Bi-dimensional measurement was defined as the pro-
duct of the longest diameter and its longest perpendicu-
lar diameter per the MacDonald criteria [13]. These
measurement were recorded for the largest radiation
necrosis lesions observed in both gadolinium-enhanced
and T2-weighted sequences [13]. Measurements were
then calculated and presented as a percentage change
from baseline MRI profiles. Other data, including dexa-
methasone dose, Karnofsky performance status (KPS),
adverse event occurrence and clinical outcomes, were alsorecorded. Toxicity was graded according the National
Cancer Institute Common Toxicity Criteria (Version 3.0).
Results
The median length of bevacizumab therapy was seven
months, and all patients were treated with a median of
four bevacizumab injections. MRI imaging revealed a
primary response assessment showing an average reduc-
tion of 54.9% and 48.4% in post-gadolinium and
T2-weighted scans, respectively. These findings indi-
cated a good and rapid response to bevacizumab treat-
ment for reversal of cerebral radiation necrosis. All
patients, with only one exception, showed significant
clinical improvement in terms of neurologic symptoms
expressed by KPS. KPS elevation was seen in 16 patients,
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patient exhibited no change in KPS score. Additionally, a
single patient with metastatic brain cancer originating
from colon cancer did not show significant clinical im-
provement or reduction of edema area by MRI analysis
even after four cycles of bevacizumab treatment. No
worsening symptoms were observed in any patients dur-
ing treatment with low dose dexamethasone until two
months after the last cycle of bevacizumab treatment.
The median length of follow-up was 6 months (4 to
12 months) after the last dose of bevacizumab. Of the 17
included patients, 10 showed clinical improvement at
the end of the follow-up period. The other seven
patients died from tumor progression (five patients),
recurrent radiation necrosis four months after bevacizu-
mab treatment (one patient), and uncontrolled cerebral
edema due to radiation necrosis (one patient).
Notably, T1-weighted gadolinium-enhanced and
T2-weighted MRI images before (Figure 1A, B) and after
(Figure 1C, D) bevacizumab treatment indicate that
bevacizumab treatment decrease perilesional edema
caused by radiation necrosis. The patient shown receivedFigure 1 MRI images before (A, B) and after (C, D) bevacizumab treat
bevacizumab (7.5 mg/kg, two-week intervals) for brain metastatic tumor fro
cyberknife treatment system based FSRT with 31.5 Gy in three fractions sevtwo cycles of bevacizumab (7.5 mg/kg, at two-week
intervals) for a brain metastatic tumor from non-small
cell lung carcinoma cancer. The patient also received
cyberknife treatment system based FSRT with 31.5 Gy in
three fractions seven months prior to treatment.
At the time of registration, dexamethasone dosages
ranged from 10 to 17.5 mg/day (median = 15 mg) before
bevacizumab treatment. Dosage reduction was achieved
in all patients four weeks after initiation of bevacizumab
treatment. A total of four patients successfully disconti-
nued dexamethasone therapy at that time.
Bevacizumab-related adverse events of grade II or less
occurred in three patients. Hypertension, subsequently
treated by oral medication, occurred in one patient after
the second bevacizumab injection. A single patient
reported temporary fatigue after the first bevacizumab
injection, which later resolved spontaneously. Protein-
uria (++) accompanied by positive fecal occult blood
testing (++) was observed after two injections in the pa-
tient with brain metastasis of colon cancer, though the
signs were not found aggravated in the remaining
follow-up studies. No indications of previously reportedment in Patient No. 5. Patient No. 5 (Table 1) received two cycles of
m non-small cell lung carcinoma cancer. The patient also received
en months prior to treatment.
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including gastrointestinal perforation, cerebral hemorrhage,
arterial thromboembolic event and infusion reaction were
observed in the current study.
Discussion
Bevacizumab has the ability to reverse radiation necrosis
in patients previously treated with conventional radi-
ation therapy for brain cancer. The current findings sug-
gest that bevacizumab treatment represents no severe
risks for patients, unlike some previous studies. The
potential beneficial effects of bevacizumab treatment on
radiation necrosis were first reported by Gonzalez et al.
[3] in a retrospective analysis published in 2007 in which
all eight patients treated with bevacizumab showed
radiographic improvement with an average of 44% re-
duction in gadolinium-enhanced MRI studies and
59.75% reduction in FLAIR MRI studies. The current
study reports similarly large reductions in necrotic tissues
after bevacizumab treatment. In the current study, average
dexamethasone dosages prior to bevacizumab treatment
were 10.5 mg/day. These treatments were gradually
reduced to an average of 3 mg/day. This remarkable
reduction was thought to be the result of restoration of
the blood brain barrier by bevacizumab action. In 2008,
Wong et al. reported a significant improvement in
patients with neurocognitive deficits after bevacizumab
therapy, as observed through imaging [6]. In a randomized
double-blind placebo-controlled trial of bevacizumab
treatment in 14 patients with radiation necrosis of the
central nervous system, bevacizumab (7.5 mg/kg) or saline
was administered intravenously at three-week intervals in
the treatment and placebo-controlled groups, respectively.
All bevacizumab-treated patients showed improvement in
clinical neurological symptoms and signs [5]. Thus, it has
been well established that bevacizumab is capable of im-
proving overall neurological signs and symptoms in
patients suffering from symptomatic radiation necrosis.
Despite these positive findings, further study of the
effects of bevacizumab on patients of different populations
is merited due to the remaining controversy regarding the
efficacy and risks involved with bevacizumab treatment.
An analysis of over 40 studies on bevacizumab treatment
for radiation necrosis indicate that the majority of studies
report positive findings [14], with bevacizumab thought to
play a beneficial role in restoration of the blood–brain bar-
rier, some studies have suggested that bevacizumab may
actually have detrimental effects. One such study suggests
that while bevacizumab may have initially beneficial
results, it may soon cause over-pruning of affected blood
vessels, resulting in vascular insufficiency that can exacer-
bate hypoxia and tissue necrosis [7]. Thus, the current
study provides significant evidence to support previous
findings indicating that bevacizumab treatment does notproduce these additional risks in Chinese cerebral radia-
tion necrosis patients.
The current study suggests that bevacizumab treatment
was very well tolerated, with no findings of bevacizumab-
related toxicity greater than grade III. Serious adverse
events previously associated with bevacizumab treatment,
such as cerebral hemorrhage, gastrointestinal perforation
and arterial thromboembolic events were not observed in
this group of patients. This may be attributed to careful
screening of patients for concurrent conditions, poten-
tially involved in the onset of these severe effects, prior to
inclusion. Notably, the current study also demonstrated
that bevacizumab decreases perilesional edema caused
by radiation necrosis (Figure 1), and 16 of 17 patients
achieved a significant clinical improvement in neurologic
symptoms caused by radiation necrosis. Unfortunately,
three patients experienced only a short duration of symp-
tom relief during the first bevacizumab treatment; how-
ever, four patients were able to completely discontinue
steroid use after the second bevacizumab injection. Only a
single patient responded poorly to bevacizumab treat-
ment, with a mild response indicated even in this case
based on the achievement of lowered dexamethasone
dosage. Because all patients remained on dexametha-
sone prior to bevacizumab treatment, a delayed steroid-
associated effect cannot be excluded. Therefore, further
studies will be required to confirm these findings.
Although rapid relief of radiation necrosis was achieved
in the majority of cases examined in the current study,
seven patients demonstrated aggravated clinical status
over a period of several months after cessation of beva-
cizumab therapy, wherein perifocal edemas reappeared
and enlarged. Dynamic gadolinium-enhanced and T2-
weighted MRI images and MRS studies revealed five cases
of tumor recurrence and another two cases of radiation
necrosis. No attempt was made to administer secondary
bevacizumab treatment to these patients, though the
effects of such secondary treatment merit further investi-
gation. Monomasa et al. recently reported that secondary
bevacizumab treatment resulted in improved efficacy in
controlling both radiation necrosis and edema. This treat-
ment also improved clinical symptoms at levels similar to
those observed in the initial round of treatment, though
the effect on future relapse remained undocumented [15].
The benefits of secondary bevacizumab treatment clearly
provided at least temporary relief of symptoms, suggesting
that secondary bevacizumab treatment should be recom-
mended in cases of recurrence of radiation necrosis and
edema.
The recurrence of radiation necrosis after bevacizumab
treatment raises an important issue about the optimiza-
tion of drug dosages and treatment intervals. Though four
bevacizumab doses (7.5 mg/kg) have been reported to
be sufficient for attaining long-term resolution for most
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of multiple bevacizumab treatments might be unable to
achieve long-term resolution. Levin et al. [5] reported that
two patients previously treated with four doses of bevaci-
zumab required one to two additional doses to reestablish
necrosis reduction at 36 to 38 weeks after initial bevaci-
zumab treatment. Similarly, Motomasa et al. [15] also
reported two patients with recurrent radiation necro-
sis several months after initial biweekly bevacizumab
treatment (5 mg) of six injections. These studies provide
strong evidence that future trials will be required to valid-
ate the most effective treatment regimens.
Conclusions
The current study demonstrates that bevacizumab treat-
ment shows great potential in treating cerebral radiation
necrosis caused by common forms of radiation therapy,
including EBRT, SRS and FSRT. While controversy still
exists as to both the efficacy and risk associated with
bevacizumab treatment in cerebral radiation necrosis
patients, the current findings demonstrate bevacizumab’s
impressive overall safety profile. These results confirm
previous positive findings for the ability of bevacizumab
treatment to reverse radiation necrosis, suggesting that
previous studies evidencing exacerbation of radiation
necrosis following bevacizumab treatment may have
resulted from the presence of complicating conditions,
eliminated by careful screening of the patients included in
the present study. Future studies will be necessary in order
to achieve longer, more consistent improvement or
alleviation of neurologic symptoms, cerebral radiation
necrosis, and edema through optimization of treatment
regimens and strategies.
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